EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CBP/p300 bromodomain: new promising epigenetic target

Qiuping Xiang, Yang Zhou, Yan Zhang, Yong Xu

Visualized Cancer Medicine · 2022

DOI: 10.1051/vcm/2022004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Visualized Cancer Medicine, 2022. Verfasst von Qiuping Xiang und 3 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CREB (cAMP responsive element binding protein) binding protein (CBP) and adenovirus E1A-associated 300 kDa protein (p300) are histone acetyltransferases, which are necessary for multiple cellular processes. Thus, CBP/p300 are promising potential antitumor targets. To date, despite various small molecule inhibitors of CBP/p300 bromodomain (BRD) having been reported, no specific inhibitor was approved by U.S. Food and Drug Administration (FDA). In this review, we described the discovery, optimization, binding mode evaluation, selectivity and potency evaluation, and therapeutic opportunities of our CBP/p300 bromodomain inhibitors, aiming to inspire new inhibitor design and advance drug discovery research in this field. One video presents the development of CBP/p300 bromodomain inhibitors.

Zitieren

APA

Xiang, Q., Zhou, Y., Zhang, Y., & Xu, Y. (2022). CBP/p300 bromodomain: new promising epigenetic target. Visualized Cancer Medicine. https://doi.org/10.1051/vcm/2022004

Vancouver

Xiang Q, Zhou Y, Zhang Y, Xu Y. CBP/p300 bromodomain: new promising epigenetic target. Visualized Cancer Medicine. 2022. doi:10.1051/vcm/2022004

BibTeX
@article{Xiang2022,
  author = {Xiang, Qiuping and Zhou, Yang and Zhang, Yan and Xu, Yong},
  title = {CBP/p300 bromodomain: new promising epigenetic target},
  journal = {Visualized Cancer Medicine},
  year = {2022},
  doi = {10.1051/vcm/2022004}
}
Kostenlos starten →